Study of MRG-001 for severe alcoholic hepatitis
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests a new medicine called MRG-001 for people with severe alcoholic hepatitis, a liver condition caused by heavy drinking. The study aims to see if the drug can help improve liver function and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years or older.
- You must have had jaundice (yellowing of skin or eyes) that started within the last 8 weeks.
- You must have been drinking heavily (more than 40 grams of alcohol per day for women, 60 grams for men) for at least 6 months, with less than 8 weeks of sobriety before jaundice started.
- Your liver tests must show certain levels (bilirubin > 3 mg/dL, AST between 50 and 400, ALT < 400, and AST/ALT ratio > 1.5).
- Your liver disease severity score (MELD) must be between 21 and 30.
- You must not have other liver diseases, active infections, or severe organ problems.
- You must agree to use birth control if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
This trial tests whether giving corticosteroids for a longer time, or adding a medicine called N-acetylcysteine, can help people with severe alcoholic hepatitis. It is for patients who have been drinking heavily and recently developed jaundice.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This study tests whether adding N-acetylcysteine to standard treatment helps people with severe alcoholic hepatitis. It may improve liver outcomes, especially for those with a high Maddrey score.
This trial tests a new medicine called larsucosterol to see if it helps people with severe alcohol-related hepatitis (liver inflammation from heavy drinking). If you qualify, the study will monitor your safety and recovery over 90 days.
This trial tests a combination of treatments for people with severe alcohol-related liver disease (alcoholic hepatitis) that has not responded to standard care. The goal is to improve liver function and help you stop drinking.
Hear when a new Alcoholic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.